- Home
- HOOK vs NXTC Comparison
HOOK vs NXTC Comparison
Compare HOOK & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- NXTC
- Stock Information
- Founded
- HOOK 2011
- NXTC 2015
- Country
- HOOK United States
- NXTC United States
- Employees
- HOOK N/A
- NXTC N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- NXTC Health Care
- Exchange
- HOOK Nasdaq
- NXTC Nasdaq
- Market Cap
- HOOK 9.3M
- NXTC 9.3M
- IPO Year
- HOOK 2019
- NXTC 2019
- Fundamental
- Price
- HOOK $1.47
- NXTC $0.39
- Analyst Decision
- HOOK Buy
- NXTC Strong Buy
- Analyst Count
- HOOK 4
- NXTC 2
- Target Price
- HOOK $10.67
- NXTC $3.50
- AVG Volume (30 Days)
- HOOK 134.3K
- NXTC 241.6K
- Earning Date
- HOOK 05-20-2025
- NXTC 05-01-2025
- Dividend Yield
- HOOK N/A
- NXTC N/A
- EPS Growth
- HOOK N/A
- NXTC N/A
- EPS
- HOOK N/A
- NXTC N/A
- Revenue
- HOOK $43,946,000.00
- NXTC N/A
- Revenue This Year
- HOOK N/A
- NXTC N/A
- Revenue Next Year
- HOOK N/A
- NXTC N/A
- P/E Ratio
- HOOK N/A
- NXTC N/A
- Revenue Growth
- HOOK 118.32
- NXTC N/A
- 52 Week Low
- HOOK $0.72
- NXTC $0.22
- 52 Week High
- HOOK $10.50
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- HOOK 67.61
- NXTC 40.48
- Support Level
- HOOK $1.14
- NXTC $0.34
- Resistance Level
- HOOK $1.67
- NXTC $0.52
- Average True Range (ATR)
- HOOK 0.16
- NXTC 0.06
- MACD
- HOOK 0.10
- NXTC 0.01
- Stochastic Oscillator
- HOOK 78.69
- NXTC 24.58
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.